Newron and Zambon along with US WorldMeds announced the launch of Xadago (safinamide) tablets as add-on therapy for patients with Parkinson’s disease (PD) currently taking levodopa/carbidopa and experiencing “off” episodes. Xadago is the first new treatment approved for PD-related motor fluctuations in over 10 years.
Xadago, a MAO-B inhibitor, works by blocking the breakdown of dopamine thus increasing dopaminergic activity in the brain. An “off” episode refers to a period where the patient’s medications are not effective, causing more PD symptoms such as tremor and difficulty walking.
The efficacy of Xadago was established in studies involving >1,100 PD patients who were taking levodopa/carbidopa and experiencing “off” time. Treatment with Xadago resulted in more beneficial “on” time vs. placebo. Patients taking Xadago also experienced less “off” time and better scores on a measure of motor function performed during “on” time vs. prior to treatment.
Xadago is available as 50mg and 100mg strength tablets in 30- and 90-count bottles.
For more information visit Xadago.com.
This article originally appeared on MPR